Company news

Share this article:

GlaxoSmithKline has inked a deal worth as much as $425 million to develop drugs for respiratory and cardiovascular disease with San Diego company Amira Pharmaceuticals. The deal will give GSK worldwide rights to develop, manufacture and sell experimental compounds including an experimental asthma treatment known as AM103, which has already has shown promise in early human trials. Amira could receive as much as $425 million in payments if it meets all of its development and regulatory milestones. It also will receive royalty payments on sales of any of its drugs.

Roska Healthcare Advertising has launched a new Web site at www.roskahealthcare.com offering visitors a virtual tour of the firm's people, clients and category experience.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.

AbbVie's files all-oral HCV drug with FDA

AbbVie's all-oral HCV treatment filed off six Phase-III trials spanning 25 countries and 2,300 patients

Rumor: Pfizer offered to buy AstraZeneca

The rumored $101 billion bid would give Pfizer a foothold in imuno-oncology and diabetes.